Akebia Therapeutics, Inc. stock is down -6.8% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 9 February’s closed higher than January.
Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!